1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Bioteque Corporation

Bioteque Corporation

TTPEX:4107
108.00
TWD
-0.50
(-0.46%)
8.46EPS
13.52P/E
7.97BMarket Cap
Nov 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.06
13.25
16.24
20.3
20.49
23.28
26.82
28.11
26.34
29.01
28.06
29.91
30.82
32.05
Basic EPS, GAAP
2.71
3.43
4.07
5.17
4.39
5.84
6.7
7.05
6.22
7.12
6.53
7.62
7.78
8.5
Free Cash Flow per Basic Share
1.91
1.13
3.86
3.52
3.94
5.09
6.98
6.68
-1.18
-1.19
8.75
8.72
8.75
8.57
Dividend per Share
1.58
1.78
2.32
2.6
3
3.5
4
4
4
4.5
4.5
4.5
5
5
Book Value per Share
19.29
21.98
27.45
29.98
30.83
33.39
35.9
38.45
40.45
43.75
46.03
49.65
52.05
50.91
Tangible Book Value per Share
19.29
21.98
27.45
29.98
30.83
33.39
35.9
38.45
40.45
43.75
46.03
49.65
52.05
50.91
Basic Weighted Avg Shares
79
85
78
69
69
69
69
69
69
69
69
69
69
69
Sales/Revenue/Turnover
958
1,124
1,259
1,407
1,420
1,613
1,859
1,948
1,825
2,010
1,945
2,073
2,135
2,221
Operating Margin (%)
24.69
26.55
29.24
31.18
30.15
30.33
31.23
31.16
30.02
28.77
29.83
31.03
31.39
32.46
Depreciation Expense
68
66
73
78
79
86
96
112
122
132
156
163
172
173
Net Income, GAAP
215
291
316
358
304
405
464
489
431
494
453
528
539
589
Effective Tax Rate (%)
13.46
13.53
21.19
18.71
22.68
21.4
21.67
18.8
19.87
20.8
20.54
22.13
20.08
21.63
Profit Margin (%)
22.47
25.89
25.07
25.46
21.4
25.11
24.97
25.09
23.62
24.55
23.27
25.49
25.25
26.54
Working Capital
1,058
1,088
966
1,070
1,185
1,305
1,451
1,647
1,351
1,344
1,509
1,650
1,786
1,627
LT Debt
154
159
57
40
45
10
11
322
415
824
734
582
439
355
Total Equity
1,616
1,882
1,898
2,077
2,137
2,314
2,488
2,664
2,803
3,032
3,190
3,441
3,607
3,528
Return on Invested Capital (%)
12.48
13.05
13.18
15.63
14.13
15.78
17.85
17.2
13.61
12.53
11.35
11.91
12.56
13.87
Return on Capital (%)
13.45
15.06
14.78
16.21
13.34
17.1
18.75
17.47
13.66
13.84
11.56
12.96
13
14.88
Return on Common Equity (%)
14.88
16.63
16.71
18.02
14.42
18.2
19.33
18.97
15.78
16.92
14.55
15.93
15.3
17.29

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
158
145
144
LT Borrowings
153
105
76
LT Finance Leases
286
282
279
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
8,350
8,073
7,969

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,333
2,457
2,558
Cash, Cash Equivalents & STI
1,668
1,797
1,871
Accounts Receivable, Net
244
218
230
Inventories
294
300
312
Total Current Liabilities
547
973
931
Payables & Accruals
- -
- -
- -
ST Debt
158
145
144
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.65%
6.26%
4.83%
Free Cash Flow
-89.86%
-190.8%
0.42%
Net Income, GAAP
6.46%
2.64%
2.07%
Sales/Revenue/Turnover
5.64%
2.04%
3.03%
Total Cash Common Dividend
- -
- -
11.11%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
496
519
553
504
2,073
2025
519
530
519
567
2,135
2026
546
588
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.81
1.8
2.08
1.94
7.62
2025
1.94
1.62
1.97
2.24
7.78
2026
2.09
2.2
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.5
2025
- -
- -
5
- -
5
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jin-Long Lin
Full Time Employees
385
Sector
Health technology
Industry
Medical specialties
Address
No. 23 Chang-An East Road Taipei TPE Taiwan 104
IPO Date
Jan 2, 2002
Website
bioteq.com.tw
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bioteque Corporation (4107.TWO) manufactures and markets a broad range of disposable medical devices focused on hemodialysis access, endovascular interventions, respiratory care, and related therapeutic areas; its core products include hemodialysis blood tubing lines, A-V fistula needles, transducer protectors, online HDF sets, closed suction catheters, endotracheal tubes, PTA balloon dilatation catheters, angiographic catheters, sheath introducers, guidewires, pigtail drainage catheter sets, ureteral stents, PCN kits, dialysis catheters, IV infusion bags, precision IV sets, drainage bags, and an extensive array of medical components such as luer locks, drip chambers, filters, clamps, and dialyzer connectors. The company operates manufacturing facilities in Taiwan, including its headquarters facility and the recently completed flagship plant in Yilan Science Park established in 2023 to enhance production capacity and provide comprehensive contract development and manufacturing organization (CDMO) services, as well as a facility in the Philippines; it serves markets across Asia, North America, South America, and other international regions. Founded in 1991 and listed on the Taipei Exchange since 2002, Bioteque Corporation is headquartered at No. 23, Sec. 1, Chang-An East Road, Taipei, Taiwan, and employs over 1,100 people group-wide with facilities accredited to ISO 13485, compliant with FDA, GMP, and EU CE standards. In recent developments, the company completed its new state-of-the-art Yilan Industrial Park facility, boosting capacity for OEM, ODM, OBM, and CDMO orders to capture post-pandemic global demand shifts and support revenue growth, as reflected in its third quarter 2025 earnings release showing EPS of NT$1.97; it continues to pursue product innovations like advanced silicone and TPU catheters while strengthening distributor alliances and sales channels.